Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioreason Inc.

This article was originally published in Start Up

Executive Summary

Understanding what makes one compound a hit or a miss is important in figuring out how to improve a screen. BioReason offers intelligent software on a per client basis by incorporating both specifics about a particular screen and the company's human expertise, to create artificially intelligent programs.

You may also be interested in...



Start-Ups in High Throughput Screening

Companies in the new generation of screening technologies are stressing content as much as they're stressing speed, and one-stop shopping as much as focused expertise.

Women's Health: Too early or Too Late?

As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.

EPIcyte Pharmaceutical Inc.

EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel